Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1807 results
April 2020
-
Key ReleaseNovartis conserve une forte performance opérationnelle au 1er trimestre, confirme à ce stade les prévisions pour 2020 et fournit de grands efforts pour contribuer à la réponse mondiale au Covid-19Au 1er trimestre 2020, chiffre d’affaires net des activités poursuivies1 en hausse de 13% (tcc2, +11% USD) avec une croissance à deux chiffres (tcc) d’Innovative Medicines et de Sandoz: Les…
-
A visual tour of scientific strategies for combating coronavirus
Researchers around the world are collaborating to provide solutions to immediate and future challenges.
-
StatementNovartis announces flexible return to office and on-site field activities, starting May 11, 2020
-
Media ReleaseNovartis announces data showing Jakavi® (ruxolitinib) more effective than best available therapy in acute graft-versus-host diseaseData from Phase III REACH2 study, published in The New England Journal of Medicine, demonstrate Jakavi can improve outcomes for patients with acute graft-versus-host disease (GvHD) who do not respond…
-
Media ReleaseNovartis Kymriah® receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphomaIf approved, relapsed or refractory (r/r) follicular lymphoma would become the third B-cell malignancy indication for Kymriah, joining approvals in children and young adults with r/r ALL, and adults…
-
Media ReleaseAveXis Community Statement on the Coronavirus Disease (COVID-19)Dear SMA Community, Like many organizations across the United States and around the world, AveXis is closely monitoring the coronavirus disease (COVID-19) and its impact on patients, the SMA…
-
Media ReleaseNovartis announces new Mayzent® (siponimod) data show sustained effect in delaying disability for up to five years in patients with secondary progressive multiple sclerosis (SPMS)New long-term data from EXPAND show patients with SPMS continuously treated with Mayzent® (siponimod) experienced lower risk of disability progression and cognitive decline than patients who delayed…
-
Featured NewsWorld Malaria Day 2020
This year, World Malaria Day is happening as countries around the world are fighting the COVID-19 pandemic.
-
Going the extra mile to keep clinical trials on track during the COVID-19 pandemic
A Novartis team couriers an experimental treatment across Europe to a patient as transit grinds to a halt.
-
Media ReleaseNovartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patientsNovartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease Trial…
-
Media ReleaseNovartis acquires Amblyotech, pursuing novel digital therapy for children and adult patients with “lazy eye”Technology has potential to reimagine treatment for amblyopia (“lazy eye”), a leading cause of vision loss in children and young adults1Acquisition expands the Novartis refractive disorder pipeline…
-
StatementNovartis joins the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative
Pagination
- ‹ Previous page
- 1
- …
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- …
- 151
- › Next page